Celltrion to co-develop pill-type autoimmune disease drug with UK startup
Woo-sub Kim
Aug 20, 2020 (Gmt+09:00)
Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Pharma, the South Korean company said on August 20, a move seen as an effort to expand its presence in the monoclonal antibody biosimilar market.
Both companies will develop a pill version of infliximab, the main ingredient of Celltrion’s monoclonal antibody biosimilar Remsima.
The agreement comes after Celltriont developed the world’s first intravenous injection and subcutaneous (SC)-injection types of Remsima, a biosimilar version of Janssen’s Remicade which is also a brand name of infliximab.